Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

UFS Business School positioned as key partner in the fight against fraud
2016-11-21

A collaborative effort to curb the scourge of fraud in public and private companies has been identified as the most effective method at the launch of International Fraud Awareness week, 13-19 November.  The programme kicked off with a media briefing held in Bloemfontein, under the theme: “Curb Fraud and Accelerate Economic Transformation”.  At this occasion, the Free State Provincial Treasury and key partner institutions which are: UFS Business School, Standard Bank, Association of Certified Fraud Examiners (ACFE), and PricewaterhouseCoopers, made a pronouncement on their efforts to stop fraud in public and private institutions.

Strategic partnerships empower companies
The UFS Business School, in collaboration with Strategic Investigations and Seminars, formed a collaborative effort to present the Advanced Certificate in Fraud Examination, thus empowering individual companies to have within their ranks, certified fraud examiners.  The programme is a registered SAQA, NQF level 7 course comprising four modules; Law, Investigation, Fraud Prevention, Detection and Ethics, Financial Transactions and Fraud Schemes. Students are assisted to continue to the ACFE Board examination in order to become internationally accredited. In 2016, a new e-learning model was introduced to decrease the time spent away from the workplace, thereby encouraging more professionals to enrol.

Commitment is key driving force

Speaking at the media briefing, Jo’Anni Deacon, Senior Officer at the UFS Business School, said “by presenting the programme, the university had positioned itself as a key partner with provincial government and other entities in the fight against fraud”.

Head of Department in the Free State Provincial Treasury, Godfrey Mahlatsi, reiterated the stance of zero tolerance against fraud, and that the department was committed to ensuring that this partnership continued to grow, enabling all to strengthen the message that fraud and corruption undermined the goals and objectives of the National Development Plan.

Gerhard Geldenhuys, Director of PwC Forensic Services said: “I believe we are making a difference and further believe that the time for dialogue on fraud is now better than ever.”

The week-long campaign encourages employees (both in the public and private sector), and business leaders, to proactively take action to minimise the impact of fraud in their environments.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept